Prestige Consumer Healthcare Inc. (PBH) financials: revenue, earnings and cash flow
Fiscal 2017–2026 + TTM · from SEC filings · data as of November 13, 2026
Summary
Prestige Consumer Healthcare’s revenue went from $882M in fiscal 2017 to $1.1B in fiscal 2026, growth of about 2.4% a year.
Net income in fiscal 2026 was $190M, a net margin of 17.5%; the best year in this period was 2018 with $340M.
Over the twelve months to September 30, 2026, revenue was $1.2B and net income $155M.
Free cash flow was $246M in fiscal 2026 and positive in 10 of the 10 years shown.
The diluted share count fell 9% over the period (buybacks).
Revenue, profit and cash flow by year
Income statement
| Fiscal year | TTM | 2026 | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $1.2B | $1.1B | $1.1B | $1.1B | $1.1B | $1.1B | $943M | $963M | $976M | $1.0B | $882M |
| Gross profit | $612M | $596M | $634M | $624M | $625M | $621M | $547M | $552M | $556M | $577M | $500M |
| Operating income | $291M | $309M | $337M | $342M | -$22M | $330M | $297M | $291M | $68M | $215M | $206M |
| Net income | $155M | $190M | $215M | $209M | -$82M | $205M | $165M | $142M | -$36M | $340M | $69M |
| EPS (diluted) | $3.24 | $3.91 | $4.29 | $4.17 | $-1.65 | $4.04 | $3.25 | $2.78 | $-0.69 | $6.34 | $1.30 |
| R&D | — | — | — | — | — | — | — | — | — | — | — |
| Revenue growth | — | −4.3% | +1.1% | −0.2% | +3.8% | +15.2% | −2.0% | −1.3% | −6.3% | +18.0% | +9.4% |
Cash flow
| Fiscal year | TTM | 2026 | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | $230M | $258M | $252M | $249M | $230M | $260M | $236M | $217M | $189M | $210M | $149M |
| Capital spending | -$16M | -$11M | -$8M | -$10M | -$8M | -$10M | -$22M | -$15M | -$10M | -$13M | -$3M |
| Free cash flow | $214M | $246M | $243M | $239M | $222M | $250M | $213M | $203M | $179M | $198M | $146M |
| Dividends paid | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Buybacks | $47M | $156M | $52M | $25M | $50M | $0 | $12M | $57M | $50M | $0 | $0 |
| Stock-based pay | $11M | $11M | $11M | $14M | $12M | $9M | $9M | $8M | $7M | $9M | $8M |
Balance sheet
| Fiscal year | TTM | 2026 | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash | — | $64M | $98M | $46M | $58M | $27M | $32M | $95M | $28M | $33M | $42M |
| Debt | — | $1.0B | $1.0B | $1.1B | $1.4B | $1.5B | $1.5B | $1.8B | $1.8B | $2.0B | $2.2B |
| Equity | — | $1.9B | $1.8B | $1.7B | $1.4B | $1.6B | $1.4B | $1.2B | $1.1B | $1.2B | $823M |
| Total assets | — | $3.5B | $3.4B | $3.3B | $3.4B | $3.7B | $3.4B | $3.5B | $3.4B | $3.8B | $3.9B |
| Shares (diluted) | 48M | 49M | 50M | 50M | 50M | 51M | 51M | 51M | 52M | 54M | 53M |
Margins and returns
| Fiscal year | TTM | 2026 | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross margin | 52.5% | 54.7% | 55.8% | 55.5% | 55.5% | 57.1% | 58.0% | 57.3% | 56.9% | 55.4% | 56.7% |
| Operating margin | 25.0% | 28.4% | 29.6% | 30.4% | -2.0% | 30.4% | 31.5% | 30.2% | 6.9% | 20.7% | 23.3% |
| Net margin | 13.3% | 17.5% | 18.9% | 18.6% | -7.3% | 18.9% | 17.5% | 14.8% | -3.7% | 32.6% | 7.9% |
| FCF margin | 18.4% | 22.6% | 21.4% | 21.3% | 19.7% | 23.0% | 22.6% | 21.0% | 18.3% | 19.0% | 16.5% |
| ROIC | — | 7.9% | 8.9% | 9.3% | -0.7% | 8.4% | 8.4% | 7.4% | 2.2% | 5.3% | 4.2% |
| ROE | — | 10.1% | 11.7% | 12.7% | -5.7% | 13.0% | 12.1% | 12.2% | -3.3% | 28.8% | 8.4% |
Frequently asked questions
What is Prestige Consumer Healthcare’s annual revenue?
$1.1B in fiscal 2026 and $1.2B over the twelve months to September 30, 2026.
How much profit does Prestige Consumer Healthcare make?
Net income was $190M in fiscal 2026 (net margin 17.5%).
Is Prestige Consumer Healthcare’s revenue growing?
No: revenue fell 4.3% in fiscal 2026 compared with the year before.
From the company’s 10-K and 10-Q filings with the SEC; per-share figures adjusted for stock splits. Rebuilt daily. Not investment advice.